-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 9, CStone Pharmaceuticals announced that at the 2021 World Lung Cancer Conference (2021 IASLC WCLC) organized by the International Association for the Study of Lung Cancer, the company announced the selective RET inhibitor Pugeta® (Platin) in the form of an oral report.
The ARROW study (ClinicalTrials.
Effectiveness: Regardless of whether it has been treated in the past, Pugeta® has achieved rapid and long-lasting clinical activity in Chinese patients with RET fusion-positive advanced NSCLC
Patients who have previously received platinum-based chemotherapy (n=33.
The confirmed objective response rate (ORR) was 66.
Among 22 patients with confirmed remission, the median time to first remission was 1.
Patients who have not received systemic treatment (n=30.
The confirmed ORR was 80%, including 2 cases of complete remission and 22 cases of partial remission, and the DCR was 86.
Among 24 patients with confirmed remission, the median time to first remission was 1.
Safety: Pugeta® is well tolerated and safety is controllable
Pugeta® is well tolerated, and is overall safe and controllable in Chinese patients, and no new safety signals have been found
Note: The original text has been deleted